Physician profile
Albene Kokocinski
NPI 1053346221
$5,602.30
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $868 · 2021: $1,350 · 2022: $943 · 2023: $880 · 2024: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $942.01 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $929.30 | 2019-2024 | |
| Abbvie INC. | $910.95 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.93 | 2019-2022 | |
| Amgen INC. | $345.71 | 2019-2023 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $315.12 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $193.23 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.25 | 2019-2022 | |
| Astellas Pharma US INC | $178.22 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.37 | 2021-2023 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $155.00 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $130.16 | 2019-2022 | |
| Exact Sciences Corporation | $87.42 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $76.65 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $75.97 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $69.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $64.10 | 2020-2023 | Shingrix, Arexvy |
| Ibsa Pharma INC. | $51.06 | 2021-2022 | |
| Lilly USA, LLC | $47.82 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.67 | 2019-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $40.51 | 2019 | |
| Dexcom, INC. | $40.02 | 2021 | |
| Allergan, INC. | $39.84 | 2019-2020 | |
| Hologic Sales and Service, LLC | $38.62 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.38 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26.79 | 2021 | |
| Bausch Health US, LLC | $18.07 | 2021 | |
| Genentech USA, INC. | $16.45 | 2020 | |
| Medicure Pharma INC. | $14.26 | 2023 | Zypitamag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albene Kokocinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.